צמיחת מכירות ב-12 חודשים נגררים: Pharvaris Pharma (PHVS)

Investor interest in Pharvaris N.V. (PHVS) has temporarily declined due to FDA restrictions, which disrupted the integrity of the edema therapy ecosystem. The TTM revenue growth trend illustrates current expansion, where the 0.00 metric determines the parameter status. Stability is supported by transparent European-style management and the development of convenient oral medications, enabling effective competition within the niche immunological drug segment.
Pharvaris - פילוחים אנליטיים ומדדי מפתח (PHVS)

This indicator captures the percentage change in total revenue over the last twelve months relative to the same period last year, allowing for an assessment of the market share expansion rates for Pharvaris N.V. (PHVS). By analyzing the relative year-over-year (LTM) revenue dynamics, an investor can compare sales growth rates against the high development costs of oral medications to determine the point at which the company transitions toward scaling profits.